Pharma Is Betting Big on PD-1/VEGF Bispecifics. But Are Companies Chasing the Wrong Target?

Why It Matters

The mixed efficacy signals in lung cancer could reshape multi‑billion‑dollar investment strategies, while uncovering more suitable tumor types may unlock higher returns for developers.

Key Takeaways

• ivonescimab cut lung cancer death risk 34% vs chemo+PD‑1.
• Chinese trial demographics skew male, may limit global relevance.
• VEGF bispecifics may be more effective in liver and gastric cancers.
• Companies expanding bispecific trials to colorectal, breast, and liver tumors.
• Global phase 3 data show mixed survival benefits, raising skepticism.

Pulse Analysis

The surge in PD‑1/VEGF bispecific antibodies reflects a broader industry bet on combining immune checkpoint inhibition with anti‑angiogenic therapy. Ivonescimab’s 34% mortality reduction in a Chinese phase 3 trial sparked a wave of licensing deals and multi‑billion‑dollar R&D commitments from giants such as BioNTech, Merck and Pfizer. Investors view the dual‑target approach as a way to overcome resistance mechanisms that limit the durability of single‑agent immunotherapies, positioning bispecifics as a next‑generation oncology platform.

Yet the enthusiasm is tempered by demographic and statistical caveats. The Chinese cohort was 93% male and predominantly composed of former or current smokers, a profile that diverges sharply from the more heterogeneous patient mix in the United States and Europe. Moreover, while the drug demonstrated a progression‑free survival edge in a global phase 3 readout, its overall survival benefit failed to achieve statistical significance. These nuances suggest that the apparent lung‑cancer breakthrough may not translate uniformly across markets, prompting analysts to question the robustness of the data and the wisdom of concentrating resources on this indication.

Recognizing these uncertainties, companies are diversifying their bispecific pipelines toward tumor types where VEGF signaling plays a more central role, such as hepatocellular carcinoma, gastric and colorectal cancers. Early‑stage studies indicate that liver tumors, which rely heavily on angiogenesis, could respond more favorably to simultaneous PD‑1 and VEGF blockade. By expanding trial footprints beyond lung cancer, firms aim to de‑risk their investments and capture new revenue streams. The next few years of global trial readouts will be pivotal in determining whether bispecifics become a cornerstone of oncology or remain a niche, high‑cost endeavor.